keyword
MENU ▼
Read by QxMD icon Read
search

prostate cancer selenium

keyword
https://www.readbyqxmd.com/read/28767087/novel-methylselenoesters-as-antiproliferative-agents
#1
Nuria Díaz-Argelich, Ignacio Encío, Daniel Plano, Aristi P Fernandes, Juan Antonio Palop, Carmen Sanmartín
Selenium (Se) compounds are potential therapeutic agents in cancer. Importantly, the biological effects of Se compounds are exerted by their metabolites, with methylselenol (CH₃SeH) being one of the key executors. In this study, we developed a new series of methylselenoesters with different scaffolds aiming to modulate the release of CH₃SeH. The fifteen compounds follow Lipinski's Rule of Five and with exception of compounds 1 and 14, present better drug-likeness values than the positive control methylseleninic acid...
August 2, 2017: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://www.readbyqxmd.com/read/28754796/a-prospective-study-of-chronic-inflammation-in-benign-prostate-tissue-and-risk-of-prostate-cancer-linked-pcpt-and-select-cohorts
#2
Elizabeth A Platz, Ibrahim Kulac, John R Barber, Charles G Drake, Corinne E Joshu, William G Nelson, M Scott Lucia, Eric A Klein, Scott M Lippman, Howard L Parnes, Ian M Thompson, Phyllis J Goodman, Catherine M Tangen, Angelo M De Marzo
BACKGROUND: We leveraged two trials to test the hypothesis of an inflammation-prostate cancer link prospectively in men without indication for biopsy. METHODS: Prostate Cancer Prevention Trial (PCPT) participants who had an end-of-study biopsy performed per protocol that was negative for cancer and who subsequently enrolled in the Selenium and Vitamin E Cancer Prevention Trial (SELECT) were eligible. We selected all 100 cases and sampled 200 frequency-matched controls and used PCPT end-of-study biopsies as "baseline"...
July 28, 2017: Cancer Epidemiology, Biomarkers & Prevention
https://www.readbyqxmd.com/read/28672782/vitamin-e-and-alzheimer-s-disease-is-it-time-for-personalized-medicine
#3
REVIEW
Breana Cervantes, Lynn M Ulatowski
For the last two decades, it has been hotly debated whether vitamin E-the major lipid-soluble antioxidant, which functions to maintain neurological integrity-is efficacious as a therapy for Alzheimer's disease. Several factors key to the debate, include (1) which of the eight naturally-occurring vitamin E forms should be used; (2) how combination treatments affect vitamin E efficacy; and (3) safety concerns that most-recently resurfaced after the results of the Selenium and vitamin E Cancer prevention trial SELECT prostate cancer trial...
June 24, 2017: Antioxidants (Basel, Switzerland)
https://www.readbyqxmd.com/read/28634111/levels-of-plasma-selenium-and-urinary-total-arsenic-interact-to-affect-the-risk-for-prostate-cancer
#4
Yu-Mei Hsueh, Chien-Tien Su, Horng-Sheng Shiue, Wei-Jen Chen, Yeong-Shiau Pu, Ying-Chin Lin, Cheng-Shiuan Tsai, Chao-Yuan Huang
This study investigated whether plasma selenium levels modified the risk for prostate cancer (PC) related to arsenic exposure. We conducted a case-control study that included 318 PC patients and 318 age-matched, healthy control subjects. Urinary arsenic profiles were examined using HPLC-HG-AAS and plasma selenium levels were measured by ICP-MS. We found that plasma selenium levels displayed a significant dose-dependent inverse association with PC. The odds ratio (OR) and 95% confidence interval (CI) for PC was 0...
September 2017: Food and Chemical Toxicology
https://www.readbyqxmd.com/read/28592284/biogenic-selenium-nanoparticles-induce-ros-mediated-necroptosis-in-pc-3-cancer-cells-through-tnf-activation
#5
Praveen Sonkusre, Swaranjit Singh Cameotra
BACKGROUND: Selenium is well documented to inhibit cancer at higher doses; however, the mechanism behind this inhibition varies widely depending on the cell type and selenium species. Previously, we have demonstrated that Bacillus licheniformis JS2 derived biogenic selenium nanoparticles (SeNPs) induce non-apoptotic cell death in prostate adenocarcinoma cell line, PC-3, at a minimal concentration of 2 µg Se/ml, without causing toxicity to the primary cells. However, the mechanism behind its anticancer activity was elusive...
June 7, 2017: Journal of Nanobiotechnology
https://www.readbyqxmd.com/read/28415774/chemoprevention-of-prostate-cancer-in-men-with-high-grade-prostatic-intraepithelial-neoplasia-hgpin-a-systematic-review-and-adjusted-indirect-treatment-comparison
#6
Kang Cui, Xiangnan Li, Yabing Du, Xiance Tang, Seiji Arai, Yiwei Geng, Ying Xi, Han Xu, Yue Zhou, Wang Ma, Tengfei Zhang
BACKGROUND: High-grade prostatic intraepithelial neoplasia (HGPIN) is the precursor or premalignant form of prostate cancer. At least 30% patients with a confirmed HGPIN will develop prostate cancer within 1 year after repeated biopsy. HGPIN patients are the appropriate at-risk population for chemoprevention strategies investigation against prostate cancer. However the commonly used chemoprevention agents that targeted on hormonal imbalance or lifestyle-related factors showed varied results in HGPIN patients...
May 30, 2017: Oncotarget
https://www.readbyqxmd.com/read/28412747/selenomethionine-and-methyl-selenocysteine-multiple-dose-pharmacokinetics-in-selenium-replete-men
#7
James R Marshall, Raymond F Burk, Rochelle Payne Ondracek, Kristina E Hill, Marjorie Perloff, Warren Davis, Roberto Pili, Saby George, Raymond Bergan
According to the Nutritional Prevention of Cancer (NPC) trial, a selenized yeast supplement containing selenium, 200 mcg/day, decreased the incidence of total cancer, cancers of the prostate, colon and lung, and cancer mortality. The active agent in the selenized yeast supplement was assumed to be selenomethionine (SEMET), although the supplement had not been well speciated. The SELECT study, largely motivated by the NPC trial, enrolling nearly 40 times as many subjects, showed unequivocally that selenium 200 mcg/day, with selenium in the form of SEMET, does not protect selenium-replete men against prostate or other major cancer...
April 18, 2017: Oncotarget
https://www.readbyqxmd.com/read/28319243/association-of-antioxidant-supplement-use-and-dementia-in-the-prevention-of-alzheimer-s-disease-by-vitamin-e-and-selenium-trial-preadvise
#8
RANDOMIZED CONTROLLED TRIAL
Richard J Kryscio, Erin L Abner, Allison Caban-Holt, Mark Lovell, Phyllis Goodman, Amy K Darke, Monica Yee, John Crowley, Frederick A Schmitt
Importance: Oxidative stress is an established dementia pathway, but it is unknown if the use of antioxidant supplements can prevent dementia. Objective: To determine if antioxidant supplements (vitamin E or selenium) used alone or in combination can prevent dementia in asymptomatic older men. Design, Setting, and Participants: The Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADViSE) trial began as a double-blind randomized clinical trial in May 2002, which transformed into a cohort study from September 2009 to May 2015...
May 1, 2017: JAMA Neurology
https://www.readbyqxmd.com/read/28151881/serum-selenium-levels-and-prostate-cancer-risk-a-moose-compliant-meta-analysis
#9
Zhigang Cui, Dezhong Liu, Chun Liu, Gang Liu
Some observational studies have shown that elevated serum selenium levels are associated with reduced prostate cancer risk; however, not all published studies support these results. A literature search of PubMed, Embase, Medline, and the Cochrane Library up until September 2016 identified 17 studies suitable for further investigation. A meta-analysis was conducted on these studies to investigate the association between serum selenium levels and subsequent prostate cancer risk. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were used to evaluate the overall OR of prostate cancer for the highest versus the lowest levels of serum selenium...
February 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28102015/circulating-antioxidant-levels-and-risk-of-prostate-cancer-by-tmprss2-erg
#10
RANDOMIZED CONTROLLED TRIAL
Rebecca E Graff, Gregory Judson, Thomas U Ahearn, Michelangelo Fiorentino, Massimo Loda, Edward L Giovannucci, Lorelei A Mucci, Andreas Pettersson
BACKGROUND: Few studies have considered etiological differences across molecular subtypes of prostate cancer, despite potential to improve opportunities for precision prevention of a disease for which modifiable risk factors have remained elusive. Factors that lead to DNA double-strand breaks, such as oxidative stress, may promote the formation of the TMPRSS2:ERG gene fusion in prostate cancer. We tested the hypothesis that increasing levels of pre-diagnostic circulating antioxidants, which may reduce oxidative stress, are associated with lower risk of developing TMPRSS2:ERG positive prostate cancer...
May 2017: Prostate
https://www.readbyqxmd.com/read/28076331/a-short-term-intervention-with-selenium-affects-expression-of-genes-implicated-in-the-epithelial-to-mesenchymal-transition-in-the-prostate
#11
Dieuwertje E G Kok, Lambertus A L M Kiemeney, Gerald W Verhaegh, Jack A Schalken, Emile N J T van Lin, J P Michiel Sedelaar, J Alfred Witjes, Christina A Hulsbergen-van de Kaa, Pieter van 't Veer, Ellen Kampman, Lydia A Afman
In parallel with the inconsistency in observational studies and chemoprevention trials, the mechanisms by which selenium affects prostate cancer risk have not been elucidated. We conducted a randomized, placebo-controlled trial to examine the effects of a short-term intervention with selenium on gene expression in non-malignant prostate tissue. Twenty-three men received 300 µg selenium per day in the form of selenized yeast (n=12) or a placebo (n=11) during 5 weeks. Prostate biopsies collected from the transition zone before and after intervention were analysed for 15 participants (n=8 selenium, n=7 placebo)...
February 7, 2017: Oncotarget
https://www.readbyqxmd.com/read/27998216/biases-in-recommendations-for-and-acceptance-of-prostate-biopsy-significantly-affect-assessment-of-prostate-cancer-risk-factors-results-from-two-large-randomized-clinical-trials
#12
REVIEW
Catherine M Tangen, Phyllis J Goodman, Cathee Till, Jeannette M Schenk, M Scott Lucia, Ian M Thompson
Purpose To identify factors related to who undergoes a prostate biopsy in a screened population and to estimate the impact of biopsy verification on risk factor-prostate cancer associations. Patients and Methods Men who were screened regularly from the placebo arms of two large prostate cancer prevention trials (Prostate Cancer Prevention Trial [PCPT] and Selenium and Vitamin E Cancer Prevention Trial [SELECT]) were examined to define incident prostate cancer cohorts. Because PCPT had an end-of-study biopsy, prostate cancer cases were categorized by a preceding prostate-specific antigen/digital rectal examination prompt (yes/no) and noncases by biopsy-proven negative status (yes v no)...
December 20, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27782038/the-effect-of-zinc-and-selenium-supplementation-mode-on-their-bioavailability-in-the-rat-prostate-should-administration-be-joint-or-separate
#13
Adam Daragó, Andrzej Sapota, Marzenna Nasiadek, Michał Klimczak, Anna Kilanowicz
It is thought that zinc and selenium deficiency may play a significant role in the etiology of prostate cancer. Although joint zinc and selenium supplementation is frequently applied in the prevention of prostate diseases, the bioavailability of these elements in the prostate after co-administration is still unknown. The study examines the effect of subchronic supplementation of zinc gluconate and selenium compounds (sodium selenite or selenomethionine), administered together or separately, on their bioavailability in the prostate, as well as the induction of metallothionein-like proteins (MTs) bound to zinc in the prostate and liver...
October 4, 2016: Nutrients
https://www.readbyqxmd.com/read/27777235/colorectal-adenomas-in-participants-of-the-select-randomized-trial-of-selenium-and-vitamin-e-for-prostate-cancer-prevention
#14
Peter Lance, David S Alberts, Patricia A Thompson, Liane Fales, Fang Wang, Jerilyn San Jose, Elizabeth T Jacobs, Phyllis J Goodman, Amy K Darke, Monica Yee, Lori Minasian, Ian M Thompson, Denise J Roe
Selenium and vitamin E micronutrients have been advocated for the prevention of colorectal cancer. Colorectal adenoma occurrence was used as a surrogate for colorectal cancer in an ancillary study to the Selenium and Vitamin E Cancer Prevention Trial (SELECT) for prostate cancer prevention. The primary objective was to measure the effect of selenium (as selenomethionine) on colorectal adenomas occurrence, with the effect of vitamin E (as α-tocopherol) supplementation on colorectal adenoma occurrence considered as a secondary objective...
January 2017: Cancer Prevention Research
https://www.readbyqxmd.com/read/27677361/prostate-cancer-risk-related-to-foods-food-groups-macronutrients-and-micronutrients-derived-from-the-uk-dietary-cohort-consortium-food-diaries
#15
J A Lane, S E Oliver, P N Appleby, M A H Lentjes, P Emmett, D Kuh, A Stephen, E J Brunner, M J Shipley, F C Hamdy, D E Neal, J L Donovan, K-T Khaw, T J Key
BACKGROUND/OBJECTIVES: The influence of dietary factors remains controversial for screen-detected prostate cancer and inconclusive for clinically detected disease. We aimed to examine these associations using prospectively collected food diaries. SUBJECTS/METHODS: A total of 1,717 prostate cancer cases in middle-aged and older UK men were pooled from four prospective cohorts with clinically detected disease (n=663), with routine data follow-up (means 6.6-13.3 years) and a case-control study with screen-detected disease (n=1054), nested in a randomised trial of prostate cancer treatments (ISCTRN 20141297)...
February 2017: European Journal of Clinical Nutrition
https://www.readbyqxmd.com/read/27519183/opportunities-and-challenges-in-incorporating-ancillary-studies-into-a-cancer-prevention-randomized-clinical-trial
#16
Phyllis J Goodman, Catherine M Tangen, Amy K Darke, Kathryn B Arnold, JoAnn Hartline, Monica Yee, Karen Anderson, Allison Caban-Holt, William G Christen, Patricia A Cassano, Peter Lance, Eric A Klein, John J Crowley, Lori M Minasian, Frank L Meyskens
BACKGROUND: The Selenium and Vitamin E Cancer Prevention Trial (SELECT) was a randomized, double-blind, placebo-controlled, prostate cancer prevention study funded by the National Cancer Institute and conducted by SWOG (Southwest Oncology Group). A total of 35,533 men were assigned randomly to one of four treatment groups (vitamin E + placebo, selenium + placebo, vitamin E + selenium, placebo + placebo). At the time of the trial's development, NIH had invested substantial resources in evaluating the potential benefits of these antioxidants...
August 12, 2016: Trials
https://www.readbyqxmd.com/read/27406859/tomato-based-randomized-controlled-trial-in-prostate-cancer-patients-effect-on-psa
#17
Ingvild Paur, Wolfgang Lilleby, Siv Kjølsrud Bøhn, Erik Hulander, Willibrord Klein, Ljiljana Vlatkovic, Karol Axcrona, Nils Bolstad, Trine Bjøro, Petter Laake, Kristin A Taskén, Aud Svindland, Lars Magne Eri, Bjørn Brennhovd, Monica H Carlsen, Sophie D Fosså, Sigbjørn S Smeland, Anette S Karlsen, Rune Blomhoff
BACKGROUND & AIMS: The effect of lycopene-containing foods in prostate cancer development remains undetermined. We tested whether a lycopene-rich tomato intervention could reduce the levels of prostate specific antigen (PSA) in prostate cancer patients. METHODS: Prior to their curative treatment, 79 patients with prostate cancer were randomized to a nutritional intervention with either 1) tomato products containing 30 mg lycopene per day; 2) tomato products plus selenium, omega-3 fatty acids, soy isoflavones, grape/pomegranate juice, and green/black tea (tomato-plus); or 3) control diet for 3 weeks...
June 2017: Clinical Nutrition: Official Journal of the European Society of Parenteral and Enteral Nutrition
https://www.readbyqxmd.com/read/27385803/selenium-and-prostate-cancer-analysis-of-individual-participant-data-from-fifteen-prospective-studies
#18
Naomi E Allen, Ruth C Travis, Paul N Appleby, Demetrius Albanes, Matt J Barnett, Amanda Black, H Bas Bueno-de-Mesquita, Mélanie Deschasaux, Pilar Galan, Gary E Goodman, Phyllis J Goodman, Marc J Gunter, Markku Heliövaara, Kathy J Helzlsouer, Brian E Henderson, Serge Hercberg, Paul Knekt, Laurence N Kolonel, Christina Lasheras, Jakob Linseisen, E Jeffrey Metter, Marian L Neuhouser, Anja Olsen, Valeria Pala, Elizabeth A Platz, Harri Rissanen, Mary E Reid, Jeannette M Schenk, Meir J Stampfer, Pär Stattin, Catherine M Tangen, Mathilde Touvier, Antonia Trichopoulou, Piet A van den Brandt, Timothy J Key
BACKGROUND: Some observational studies suggest that a higher selenium status is associated with a lower risk of prostate cancer but have been generally too small to provide precise estimates of associations, particularly by disease stage and grade. METHODS: Collaborating investigators from 15 prospective studies provided individual-participant records (from predominantly men of white European ancestry) on blood or toenail selenium concentrations and prostate cancer risk...
November 2016: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/27341379/synthesis-and-antitumor-activity-of-selenium-containing-quinone-based-triazoles-possessing-two-redox-centres-and-their%C3%A2-mechanistic-insights
#19
Eduardo H G da Cruz, Molly A Silvers, Guilherme A M Jardim, Jarbas M Resende, Bruno C Cavalcanti, Igor S Bomfim, Claudia Pessoa, Carlos A de Simone, Giancarlo V Botteselle, Antonio L Braga, Divya K Nair, Irishi N N Namboothiri, David A Boothman, Eufrânio N da Silva Júnior
UNLABELLED: Selenium-containing quinone-based 1,2,3-triazoles were synthesized using click chemistry, the copper catalyzed azide-alkyne 1,3-dipolar cycloaddition, and evaluated against six types of cancer cell lines: HL-60 (human promyelocytic leukemia cells), HCT-116 (human colon carcinoma cells), PC3 (human prostate cells), SF295 (human glioblastoma cells), MDA-MB-435 (melanoma cells) and OVCAR-8 (human ovarian carcinoma cells). Some compounds showed IC50 values < 0.3 μM. The cytotoxic potential of the quinones evaluated was also assayed using non-tumor cells, exemplified by peripheral blood mononuclear (PBMC), V79 and L929 cells...
October 21, 2016: European Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/27197287/selenium-or-vitamin-e-related-gene-variants-interaction-with-supplementation-and-risk-of-high-grade-prostate-cancer-in-select
#20
June M Chan, Amy K Darke, Kathryn L Penney, Catherine M Tangen, Phyllis J Goodman, Gwo-Shu Mary Lee, Tong Sun, Sam Peisch, Alex M Tinianow, James M Rae, Eric A Klein, Ian M Thompson, Philip W Kantoff, Lorelei A Mucci
BACKGROUND: Epidemiologic studies and secondary analyses of randomized trials supported the hypothesis that selenium and vitamin E lower prostate cancer risk. However, the Selenium and Vitamin E Cancer Prevention Trial (SELECT) showed no benefit of either supplement. Genetic variants involved in selenium or vitamin E metabolism or transport may underlie the complex associations of selenium and vitamin E. METHODS: We undertook a case-cohort study of SELECT participants randomized to placebo, selenium, or vitamin E...
July 2016: Cancer Epidemiology, Biomarkers & Prevention
keyword
keyword
50653
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"